Protalix BioTherapeutics Inc

Protalix Pushes EMA Dosing Change for Elfabrio While Facing Governance Probe

Protalix BioTherapeutics seeks a new Elfabrio® dosing schedule while navigating investor concerns and a fraud probe, balancing rare‑disease growth with governance scrutiny.

Protalix BioTherapeutics Inc
Health Care
Pharmaceuticals, Biotechnology & Life Sciences
AI generated

04/11/2025, 01:09

3 minutes to read

Protalix BioTherapeutics Reports Strong Q2 2025 Results with Revenue Surge and Strategic Leadership Changes

Protalix BioTherapeutics Inc. reports a 16% increase in revenues to $15.4 million in Q2 2025, driven by strong sales of Elfabrio in the Fabry disease market.

Protalix BioTherapeutics Inc
Health Care
Pharmaceuticals, Biotechnology & Life Sciences
AI generated

14/08/2025, 13:06

3 minutes to read